$15.56
5.14%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US00211Y4070
Symbol
ORKA

ARCA biopharma, Inc. Stock price

$15.56
+1.26 8.81% 1M
+5.65 57.01% 6M
-3.83 19.75% YTD
-13.24 45.97% 1Y
+0.39 2.59% 3Y
-17.29 52.63% 5Y
-700.70 97.83% 10Y
-959,220.29 100.00% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.76 5.14%
ISIN
US00211Y4070
Symbol
ORKA
Industry

Key metrics

Basic
Market capitalization
$582.7m
Enterprise Value
$254.3m
Net debt
positive
Cash
$328.4m
Shares outstanding
37.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.7
Dividends
DPS
$19.36
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
-387.9% | -109.4%
Increased
1 Year
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-113.3m | -
EBIT
$-113.3m | $-113.8m
Net Income
$-100.0m | $-81.8m
Free Cash Flow
$-97.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-229.9% | -
EBIT
-229.6% | -29.2%
Net Income
-195.4% | 2.4%
Free Cash Flow
-1,321.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
Financial Health
Equity Ratio
96.5%
Return on Equity
-21.9%
ROCE
-32.8%
ROIC
-
Debt/Equity
0.0
More
EPS
$-2.4
FCF per Share
$-2.6
Short interest
18.4%
Employees
-
Rev per Employee
-
Show more

Is ARCA biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

ARCA biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a ARCA biopharma, Inc. forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a ARCA biopharma, Inc. forecast:

Buy
93%
Hold
7%

Financial data from ARCA biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
81% 81%
-
- Research and Development Expense 95 95
290% 290%
-
-113 -113
230% 230%
-
- Depreciation and Amortization 0.03 0.03
25% 25%
-
EBIT (Operating Income) EBIT -113 -113
230% 230%
-
Net Profit -100 -100
195% 195%
-

In millions USD.

Don't miss a Thing! We will send you all news about ARCA biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ARCA biopharma, Inc. Stock News

Neutral
GlobeNewsWire
23 days ago
First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 MENLO PARK, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology compa...
Neutral
GlobeNewsWire
about one month ago
IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026
Neutral
GlobeNewsWire
2 months ago
MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the promotion of Laura Sandler to Chief Operating Officer.
More ARCA biopharma, Inc. News

Company Profile

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Head office United States
CEO Lawrence Klein
Founded 1992
Website orukatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today